KISQALI® (ribociclib) is proven to help premenopausal and postmenopausal women with HR+, HER2- metastatic breast cancer.

Important Safety Information:

What is the most important information I should know about KISQALI?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of th...

See More
Approved Uses:

KISQALI® (ribociclib) is a prescription medicine used in combination with:

  • an aromatase inhibitor to treat pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has sprea...
See More
LIVING LONGER WITH MBC

Understanding Overall Survival

Learn helpful information about how overall survival is different from progression-free survival.

LEARN MORE
SUPPORT MADE SIMPLE

KISQALI Care Patient Support

The KISQALI Care Patient Support Program offers customized services for eligible patients and information about potential financial assistance options.

SIGN UP TODAY